From July 25 to 27, 2019, the 34th Euro-Global Summit on Cancer Therapy & Radiation Oncology was held in London, UK. Professor Ma Qingyong attended the summit as the specially invited Chairman and signed the certificate of recognition for all the executive chairmen, hosts, speakers and participants.
Experts from more than 20 countries were invited to deliver lectures and presentations at this meeting to share clinical experience and research progress, aiming to promote academic exchange and scientific research sharing around the globe and jointly accelerate scientific progress in cancer and related fields and medical health of all mankind.
As the specially invited Chairman, Professor Ma Qingyong delivered the keynote presentation on "HSF1 inhibition sensitizes pancreatic cancer to gemcitabine via the suppression of cancer stem cell-like properties", which explored the role and mechanism of HSF1 in gemcitabine-induced chemotherapy resistance of pancreatic cancer. A variety of biological scientific research approaches, such as KPC transgenic mouse models, were employed to validate that HSF1 can promote the resistance of pancreatic cancer towards gemcitabine by regulating the characteristics of tumor stem cells, and the study innovatively proposes that HSF1 serves as a potential therapeutic target and provides a novel direction for the research of chemotherapy resistance of pancreatic cancer.
In the field of hepatobiliary diseases, especially pancreatic diseases, the team led by Professor Ma Qingyong has applied and completed more than 20 projects of National Natural Science Foundation of China, published nearly 200 articles in SCI-indexed journals in recent years, accomplished almost 300 pancreas disease-related operations every year, and delivered over 100 presentations reporting basic and clinical scientific research outcomes at domestic and international conferences.
